Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Fogarty, Gerald ^a   Morton, Rachael L ^b,c   Vardy, Janette ^d,e   Nowak, Anna K ^f   Mandel, Catherine ^g   Forder, Peta M ^h,i   Hong, Angela ^d   Hruby, George ^c,d,e   Burmeister, Bryan ^k,l   Shivalingam, Brindha ^d   Dhillon, Haryana ^e   Thompson, John F ^c,e,j  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Poche Centre   (Australia)

^d SYDNEY CANCER CENTRE   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j MELANOMA INSTITUTE AUSTRALIA   (Australia)

^k PRINCESS ALEXANDRA HOSPITAL   (Australia)

^l Trans Tasman Radiation Oncology Group (TROG)   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COGNITION; CONTROLLED STUDY; ELECTROCORTICOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LOCAL THERAPY; MALE; MELANOMA; MENINX DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRESCRIPTION; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STEREOTACTIC RADIOSURGERY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; WHOLE BRAIN RADIOTHERAPY; ADJUVANT THERAPY; BRAIN TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METASTASIS; MULTICENTER STUDY; PATHOLOGY;

BRAIN NEOPLASMS; HUMANS; MELANOMA; RADIOTHERAPY, ADJUVANT;

EID: 79957967246     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-142     Document Type: Article

References (17)

1. Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev 2004, 30(6):515-520. 10.1016/j.ctrv.2004.05.001, 15325032.
2. Posner JB. Management of brain metastases. Revue Neurologique 1992, 148(6-7):477-487.
3. Sampson JH, Carter JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998, 88(1):11-20. 10.3171/jns.1998.88.1.0011, 9420067.
4. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280(17):1485-1489. 10.1001/jama.280.17.1485, 9809728.
5. Fisher B, Seiferheld W, Schultz C, DeAngelis L, Nelson D, Schold SC, Curran W, Mehta M. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol 2005, 74(2):201-205. 10.1007/s11060-004-6596-9, 16193393.
6. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, et al. Stereotactic radiosurgery plus whole brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. JAMA 2006, 295:2483-2491. 10.1001/jama.295.21.2483, 16757720.
7. Broadbent AM, Hruby G, Tin MM, Jackson M, Firth I. Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. Radiotherapy and Oncology 2004, 71(3):259-265. 10.1016/j.radonc.2004.02.019, 15172140.
8. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann R-D, Carrie C, et al. Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. Journal of Clinical Oncology 2011, 29(2):134-141. 10.1200/JCO.2010.30.1655, 21041710.
9. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncology 2009, 10(11):1037-1044. 10.1016/S1470-2045(09)70263-3, 19801201.
10. Mahmood U, Kwok Y, Regine WF, Patchell RA. Whole-brain irradiation for patients with brain metastases: still the standard of care. Lancet Oncology 2010, 11(3):221-223. 10.1016/S1470-2045(09)70389-4, 20202606.
11. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 2003, 21:3557-3558. 10.1200/JCO.2003.07.080, 12913103.
12. Meyers CA, Geara F, Wong PF, Morrison WH. Neurocognitive effects of therapeutic irradiation for base of skull tumors. Int J Radiat Oncol Biol Phys 2000, 46(1):51-55. 10.1016/S0360-3016(99)00376-4, 10656372.
13. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004, 1(22):157-165.
14. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-376. 10.1093/jnci/85.5.365, 8433390.
15. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996, 5:139-150. 10.1007/BF00435979, 8901377.
16. Pocock SJ. Clinical trials: a practical approach. 1983, Chichester: John Wiley & Sons.
17. Roos DE, Wirth A, Burmeister BH, Spry NA, Drummond KJ, Beresford JA, McClure BE. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiotherapy and Oncology 2006, 80(3):318-322. 10.1016/j.radonc.2006.08.004, 16956684.